Oramed Pharmaceuticals

Company Overview

Snapshot

Founded in March 2006 by Nadav Kidron and Miriam Kidron, Oramed Pharmaceuticals operates with 11–50 employees. The company has raised a total of $149.13 million across 10 funding rounds from 3 investors. In October 2025, Oramed released a letter to shareholders highlighting developments in its oral insulin program, significant investment appreciation, and upcoming growth initiatives, including the launch of a new U.S. trial.

Business overview

Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing oral delivery solutions for drugs currently administered via injection. Its proprietary platform technology enables the oral administration of protein-based therapies. The company's flagship product is an oral insulin capsule, ORMD-0801, which is in advanced Phase 3 clinical trials for the treatment of type 2 diabetes under the US FDA and European EMA. Oramed operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, serving the pharmaceutical industry across markets including Asia, the United States, and Europe.

Strategic signal

In October 2024, Oramed Pharmaceuticals announced a restructuring of its debt with Scilex Holding Company. This strategic financial maneuver indicates Oramed's active management of its investment portfolio and financial obligations, which is a key signal for investors regarding the company's operational stability and its ability to navigate complex financial landscapes while continuing its core pharmaceutical development.

Company Intelligence Q&A

What is Oramed Pharmaceuticals' primary focus?

Oramed Pharmaceuticals focuses on developing proprietary platform technology for the oral delivery of drugs that are currently administered via injection, aiming to transform injectable therapies into oral treatments.

When did Oramed Pharmaceuticals go public?

Oramed Pharmaceuticals went public on NASDAQ in April 2006 and on TASE in July 2017.

What is the status of Oramed's oral insulin program?

In October 2025, Oramed Pharmaceuticals released a letter to shareholders highlighting developments in its oral insulin program, including the launch of a new U.S. trial, indicating continued advancement and investment in this key product.

What was a significant financial transaction for Oramed Pharmaceuticals in September 2023?

In September 2023, Oramed Pharmaceuticals announced a $101,875,000 short-term senior secured note transaction with Scilex Holding Company.

What was the nature of Oramed Pharmaceuticals' partnership with Hefei Tianhui Incubator of Technologies?

In December 2015, Oramed Pharmaceuticals secured funding from Hefei Tianhui Incubator of Technologies, which was followed by an additional milestone payment in October 2016.